CA2999192C - Oligonucleotides antisens hybrides avec un element cle de la region de la polyadenylation d'un transcrit primaire de dux4 et utilisations connexes - Google Patents

Oligonucleotides antisens hybrides avec un element cle de la region de la polyadenylation d'un transcrit primaire de dux4 et utilisations connexes

Info

Publication number
CA2999192C
CA2999192C CA2999192A CA2999192A CA2999192C CA 2999192 C CA2999192 C CA 2999192C CA 2999192 A CA2999192 A CA 2999192A CA 2999192 A CA2999192 A CA 2999192A CA 2999192 C CA2999192 C CA 2999192C
Authority
CA
Canada
Prior art keywords
mrna
dux4
antisense oligonucleotide
vector
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2999192A
Other languages
English (en)
Other versions
CA2999192A1 (fr
Inventor
Julie Dumonceaux
Thomas Voit
John George Dickson
Linda Jane Popplewell
Original Assignee
Institute of Myology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Myology filed Critical Institute of Myology
Priority claimed from PCT/EP2016/072447 external-priority patent/WO2017050836A1/fr
Publication of CA2999192A1 publication Critical patent/CA2999192A1/fr
Application granted granted Critical
Publication of CA2999192C publication Critical patent/CA2999192C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des acides nucléiques, des compositions et des méthodes pour le traitement de maladies, en particulier pour le traitement de la dystrophie facio-scapulo-humérale.
CA2999192A 2015-09-21 2016-09-21 Oligonucleotides antisens hybrides avec un element cle de la region de la polyadenylation d'un transcrit primaire de dux4 et utilisations connexes Active CA2999192C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306467.0 2015-09-21
EP15306467 2015-09-21
PCT/EP2016/072447 WO2017050836A1 (fr) 2015-09-21 2016-09-21 Oligonucléotides antisens et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2999192A1 CA2999192A1 (fr) 2017-03-30
CA2999192C true CA2999192C (fr) 2025-12-02

Family

ID=

Similar Documents

Publication Publication Date Title
US20180237775A1 (en) Antisense oligonucleotides and uses thereof
US11920132B2 (en) Oligonucleotide therapy for Leber congenital amaurosis
JP5894543B2 (ja) 神経筋疾患の治療のための修飾型Ｕ７ｓｎＲＮＡ
JP7659291B2 (ja) スターガルト病の治療のためのアンチセンスオリゴヌクレオチド
CA2847664C (fr) Oligonucleotides antisens pour le traitement de l'amaurose congenitale de leber
EP3759220A1 (fr) Prévention de l'inclusion de l'exon 7 et/ou de l'exon 8 dans un arnm de protéine précurseur de l'amyloïde (app)
US20190300881A1 (en) Method of treatment
JP2025020293A (ja) アンチセンスオリゴヌクレオチドは、ａｂｃａ４の異常スプライシングをレスキューする
CA3171436A1 (fr) Sequences antisens pour le traitement de la sclerose laterale amyotrophique
EP3253874B1 (fr) Traitement de la dystrophie facioscapulohumérale
WO2024228119A1 (fr) Inhibiteurs de miarn-485
EP4118436A1 (fr) Méthodes de diagnostic utilisant l'expression de sirt1
EA043834B1 (ru) Антисмысловые олигонуклеотиды для лечения болезни штаргардта